Attention Shareholders of Revance Therapeutics: Know Your Rights Before March 2025

Attention Revance Therapeutics Shareholders



Shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) are encouraged to take immediate action regarding their investment. The Gross Law Firm has issued a critical notification urging shareholders who acquired shares between February 29, 2024, and December 6, 2024, to reach out concerning their rights. This outreach is especially important given the recent allegations against the company, which could significantly impact shareholder values and considerations for taking legal action.

Understanding the Allegations


During the specified class period, Revance is accused of making materially false statements and failing to disclose critical information that placed investors at a disadvantage. According to the complaint, the company was allegedly in breach of its Distribution Agreement with Teoxane. This agreement granted Revance exclusive rights to market and distribute Teoxane's dermal fillers. Violating this agreement not only exposed Revance to legal challenges but also led to considerable financial and reputational risks.

The consequences of these allegations extend beyond mere legal implications. Reports suggest that these breaches have made the company susceptible to delays and amendments in vital business transactions, including a tender offer that could dramatically alter its operational landscape. This situation raises serious questions about the integrity of Revance's communications to its shareholders during that period.

Participation in Class Action


For existing shareholders, there is a limited timeframe to act. The deadline for registering with The Gross Law Firm as a potential lead plaintiff is March 4, 2025. Interested parties are reminded that registering as a lead plaintiff isn’t essential to recover potential losses; any shareholder who purchased RVNC shares during the identified class period is entitled to participate in the class action, regardless of their lead status.

When a shareholder registers, they will continuously receive updates and status reports related to the ongoing case through portfolio monitoring tools. This proactive communication ensures that investors remain informed and can engage meaningfully in the process as it unfolds.

The Role of The Gross Law Firm


The Gross Law Firm prides itself on being a nationally recognized class action law firm. They advocate for investors who fall victim to fraudulent practices or adverse corporate behaviors that harm shareholders. Their mission centers on the principle of responsible corporate conduct, and they work diligently to hold companies accountable for any deceitful practices that inflate stock values through falsehoods or omissions.

Shareholders facing losses are encouraged to understand their rights and take action promptly.

Contact Information


To learn more or to participate in the class action suit, shareholders can visit The Gross Law Firm's website or contact them directly at:

  • - Phone: (646) 453-8903
  • - Address: The Gross Law Firm, 15 West 38th Street, 12th floor, New York, NY, 10018
  • - Email: [email protected]

Time is of the essence, and shareholders of Revance Therapeutics, Inc. must act now to protect their interests before the upcoming March deadline.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.